| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1112645983 |
| P356 | DOI | 10.1186/S12943-019-0989-Z |
| P932 | PMC publication ID | 6408771 |
| P698 | PubMed publication ID | 30849971 |
| P50 | author | Yongguang Tao | Q57565387 |
| P2093 | author name string | Lei Zhang | |
| Shuang Liu | |||
| Fenglei Yu | |||
| Ziwei Chen | |||
| Yiyi Liang | |||
| Shifu Li | |||
| Yongan Meng | |||
| Fanyuan Zeng | |||
| P2860 | cites work | Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection | Q89400755 |
| Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial | Q90290983 | ||
| The association between markers of tumour cell metabolism, the tumour microenvironment and outcomes in patients with colorectal cancer | Q90304491 | ||
| The role of tumor DNA as a diagnostic tool for head and neck squamous cell carcinoma | Q90783734 | ||
| Aryl hydrocarbon receptor activated by benzo (a) pyrene promotes SMARCA6 expression in NSCLC | Q90861428 | ||
| Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer | Q91626171 | ||
| KRAS mutations in ctDNA: a promising new biomarker in advanced pancreatic cancer | Q93035168 | ||
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | Q24604601 | ||
| Mitochondrial DNA in Tumor Initiation, Progression, and Metastasis: Role of Horizontal mtDNA Transfer | Q26801721 | ||
| Fragment Length of Circulating Tumor DNA | Q27308628 | ||
| Double-stranded DNA in exosomes: a novel biomarker in cancer detection | Q28237711 | ||
| Circulating mutant DNA to assess tumor dynamics | Q28289337 | ||
| Age-related clonal hematopoiesis associated with adverse outcomes | Q28386602 | ||
| Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing | Q28396153 | ||
| The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers | Q29395525 | ||
| Detection of circulating tumor DNA in early- and late-stage human malignancies | Q29615778 | ||
| Origins, structures, and functions of circulating DNA in oncology | Q30249103 | ||
| Inhibition of hydrogen sulfide biosynthesis sensitizes lung adenocarcinoma to chemotherapeutic drugs by inhibiting mitochondrial DNA repair and suppressing cellular bioenergetics. | Q30355313 | ||
| Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments | Q30667824 | ||
| Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data. | Q30985595 | ||
| Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer | Q33679694 | ||
| The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). | Q33686817 | ||
| The feasibility of using mutation detection in ctDNA to assess tumor dynamics | Q33697983 | ||
| Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient Plasma | Q33703063 | ||
| Sensitive digital quantification of DNA methylation in clinical samples | Q33761814 | ||
| Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients | Q33797039 | ||
| Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer | Q34039531 | ||
| Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts | Q34117027 | ||
| Detection and quantification of mutations in the plasma of patients with colorectal tumors | Q34132363 | ||
| Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine | Q34154619 | ||
| Cell-free nucleic acids as biomarkers in cancer patients | Q34184393 | ||
| Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. | Q34278191 | ||
| The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. | Q34317490 | ||
| Liquid biopsy: monitoring cancer-genetics in the blood | Q34356149 | ||
| Microsatellite alterations in plasma DNA of small cell lung cancer patients. | Q34394739 | ||
| Microsatellite alterations in serum DNA of head and neck cancer patients | Q34394745 | ||
| Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types | Q34457638 | ||
| Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients | Q34483980 | ||
| The Warburg Effect: How Does it Benefit Cancer Cells? | Q34509467 | ||
| Integrated digital error suppression for improved detection of circulating tumor DNA | Q34520008 | ||
| Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer | Q34533164 | ||
| Neoplastic characteristics of the DNA found in the plasma of cancer patients | Q34543792 | ||
| Prediction of breast tumor progression by integrity of free circulating DNA in serum. | Q34565015 | ||
| Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer | Q40364937 | ||
| Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes. | Q40370392 | ||
| A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker | Q40379102 | ||
| A Comparison of Cell-Free DNA Isolation Kits: Isolation and Quantification of Cell-Free DNA in Plasma. | Q40421982 | ||
| Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma | Q40424686 | ||
| Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker | Q40429621 | ||
| Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases | Q40431521 | ||
| Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer | Q40433976 | ||
| Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations | Q40442141 | ||
| Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer. | Q40473977 | ||
| Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study). | Q40475653 | ||
| Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice: A Cross-Platform Comparison of Three Different Molecular Methods for Mutation Detection | Q40487827 | ||
| EGLN1/c-Myc Induced Lymphoid-Specific Helicase Inhibits Ferroptosis through Lipid Metabolic Gene Expression Changes | Q41239680 | ||
| A five-variable signature predicts radioresistance and prognosis in nasopharyngeal carcinoma patients receiving radical radiotherapy | Q41308391 | ||
| Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer | Q41354811 | ||
| Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients | Q41524917 | ||
| Single copy-sensitive electrochemical assay for circulating methylated DNA in clinical samples with ultrahigh specificity based on a sequential discrimination-amplification strategy. | Q41671038 | ||
| 5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages. | Q42059581 | ||
| 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers | Q42084542 | ||
| Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy | Q43024864 | ||
| Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. | Q43045850 | ||
| Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer | Q43142381 | ||
| DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. | Q43540280 | ||
| Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. | Q44049892 | ||
| Decrease in Lymphoid Specific Helicase and 5-hydroxymethylcytosine Is Associated with Metastasis and Genome Instability | Q44727719 | ||
| Direct detection of early-stage cancers using circulating tumor DNA. | Q46035548 | ||
| Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. | Q46086455 | ||
| Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer | Q46209531 | ||
| Near infrared-assisted Fenton reaction for tumor-specific and mitochondrial DNA-targeted photochemotherapy | Q46341769 | ||
| Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution | Q46365334 | ||
| SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer | Q46393758 | ||
| Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing | Q46529281 | ||
| Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine | Q46633214 | ||
| 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group | Q46856633 | ||
| Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma | Q46984199 | ||
| The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. | Q47140501 | ||
| Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing | Q47200971 | ||
| A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA. | Q47691502 | ||
| Mitochondrial dysfunctions in bladder cancer: Exploring their role as disease markers and potential therapeutic targets. | Q47954584 | ||
| Prognostic and predictive biomarkers in breast cancer: Past, present and future. | Q47960261 | ||
| Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma | Q48099309 | ||
| Detection and localization of surgically resectable cancers with a multi-analyte blood test. | Q48216212 | ||
| Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff | Q48227522 | ||
| Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. | Q48243258 | ||
| DNA Clutch Probes for Circulating Tumor DNA Analysis | Q49123121 | ||
| Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer | Q49790156 | ||
| RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study | Q50041458 | ||
| Convergent therapeutic strategies to overcome the heterogeneity of acquired resistance in BRAFV600E colorectal cancer | Q50047679 | ||
| The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. | Q50050305 | ||
| Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. | Q50115874 | ||
| ESR1 methylation: a liquid biopsy-based epigenetic assay for the follow up of patients with metastatic breast cancer receiving endocrine treatment. | Q50128162 | ||
| Going With the Flow: The Promise and Challenge of Liquid Biopsies | Q50198076 | ||
| The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA. | Q50276908 | ||
| Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer. | Q50592090 | ||
| Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. | Q50860920 | ||
| Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study. | Q50996130 | ||
| Nanoplasmonic biosensor: detection and amplification of dual bio-signatures of circulating tumor DNA. | Q51053878 | ||
| Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): an (18)F-FDG PET/CT study | Q38377420 | ||
| Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial | Q38385410 | ||
| Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma | Q38679628 | ||
| Chromatin Remodeling Factor LSH Drives Cancer Progression by Suppressing the Activity of Fumarate Hydratase | Q38764407 | ||
| Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. | Q38771051 | ||
| Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma | Q38776411 | ||
| Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates | Q38793093 | ||
| Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study | Q38804089 | ||
| Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. | Q38815964 | ||
| Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. | Q38821392 | ||
| Mitochondrially targeted vitamin E succinate modulates expression of mitochondrial DNA transcripts and mitochondrial biogenesis | Q38921197 | ||
| Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. | Q38927321 | ||
| Integrating liquid biopsies into the management of cancer | Q39157824 | ||
| Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer | Q40059009 | ||
| Tumor LDH-A expression and serum LDH status are two metabolic predictors for triple negative breast cancer brain metastasis | Q40114063 | ||
| Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer | Q40178819 | ||
| Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors | Q40224466 | ||
| Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. | Q40255202 | ||
| Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. | Q40291585 | ||
| Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease | Q40296266 | ||
| EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. | Q40324544 | ||
| Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer | Q40356316 | ||
| ??? | Q94720111 | ||
| Methylome analysis identifies a Wilms tumor epigenetic biomarker detectable in blood | Q35027111 | ||
| Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. | Q35082784 | ||
| Circulating tumour markers can define patients with normal colons, benign polyps, and cancers | Q35125657 | ||
| Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. | Q35127938 | ||
| Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients | Q35212779 | ||
| Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. | Q35764682 | ||
| Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease | Q36000803 | ||
| Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA | Q36128449 | ||
| Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study | Q36229421 | ||
| Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study. | Q36233903 | ||
| Simple multiplexed PCR-based barcoding of DNA for ultrasensitive mutation detection by next-generation sequencing. | Q36295144 | ||
| DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies. | Q36370872 | ||
| Development and validation of an ultra-deep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer | Q36378903 | ||
| Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression. | Q36414816 | ||
| Mitochondrial DNA Repair through OGG1 Activity Attenuates Breast Cancer Progression and Metastasis | Q36437044 | ||
| Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients | Q36508759 | ||
| Clinical trial designs incorporating predictive biomarkers. | Q36534713 | ||
| Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance | Q36574146 | ||
| Mitochondrial DNA copy number variation across human cancers | Q36642203 | ||
| Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection | Q36785190 | ||
| The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. | Q36785251 | ||
| Efficient Capture and Isolation of Tumor-Related Circulating Cell-Free DNA from Cancer Patients Using Electroactive Conducting Polymer Nanowire Platforms | Q36882961 | ||
| Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant | Q36907216 | ||
| Quantification of Somatic Chromosomal Rearrangements in Circulating Cell-Free DNA from Ovarian Cancers | Q37110941 | ||
| Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. | Q37206520 | ||
| Circulating tumor DNA detection in lung cancer patients before and after surgery | Q37264643 | ||
| [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches | Q37433626 | ||
| The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC. | Q37507351 | ||
| Chromatin Remodeling Factor LSH is Upregulated by the LRP6-GSK3β-E2F1 Axis Linking Reversely with Survival in Gliomas | Q37541852 | ||
| Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease | Q37580040 | ||
| A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance | Q37609221 | ||
| Uncovering the role of 5-hydroxymethylcytosine in the epigenome | Q37956118 | ||
| Molecular analysis of circulating tumour cells-biology and biomarkers | Q38180320 | ||
| Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer | Q38275060 | ||
| Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. | Q51195465 | ||
| A G3BP1-interacting lncRNA promotes ferroptosis and apoptosis in cancer via nuclear sequestration of p53. | Q52339996 | ||
| Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. | Q52600964 | ||
| Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. | Q52678229 | ||
| Clinical indications for, and the future of, circulating tumor cells. | Q52721008 | ||
| Anaplastic lymphoma kinase mutation (ALK F1174C) in small cell carcinoma of the prostate and molecular response to alectinib. | Q52725395 | ||
| Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer. | Q52810661 | ||
| Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. | Q52971846 | ||
| Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer. | Q53149008 | ||
| Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. | Q53191487 | ||
| Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. | Q53487996 | ||
| Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. | Q53787362 | ||
| Circulating DNA biomarkers: a primer for metastatic colorectal cancer? | Q54258634 | ||
| Free DNA in the serum of cancer patients and the effect of therapy. | Q55492005 | ||
| ctDNA and CTCs in Liquid Biopsy - Current Status and Where We Need to Progress. | Q55496656 | ||
| Tumor-Specific Mitochondrial DNA Variants Are Rarely Detected in Cell-Free DNA. | Q55518477 | ||
| Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with -Mutated Hepatocellular Carcinoma | Q56518738 | ||
| Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus | Q56937251 | ||
| Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection | Q57044038 | ||
| Presence of fetal DNA in maternal plasma and serum | Q57075132 | ||
| Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy | Q57143867 | ||
| Assessing the Impact of Circulating Tumor DNA (ctDNA) in Patients With Colorectal Cancer: Separating Fact From Fiction | Q57170570 | ||
| Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients | Q57240090 | ||
| Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer | Q57806191 | ||
| Simple and Low-Cost Sampling of Cell-Free Nucleic Acids from Blood Plasma for Rapid and Sensitive Detection of Circulating Tumor DNA | Q57824704 | ||
| Application of Cell-free DNA Analysis to Cancer Treatment | Q58083739 | ||
| Current and future perspectives of liquid biopsies in genomics-driven oncology | Q58586693 | ||
| Measurement of plasma cell-free mitochondrial tumor DNA improves detection of glioblastoma in patient-derived orthotopic xenograft models | Q58615751 | ||
| Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients | Q58702496 | ||
| Cancer biomarkers: Written in blood | Q59091333 | ||
| Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia | Q60305981 | ||
| Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity | Q62644766 | ||
| Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using 18F-FDG PET/CT. | Q64940253 | ||
| 5-Hydroxymethylome in Circulating Cell-free DNA as A Potential Biomarker for Non-small-cell Lung Cancer. | Q64980091 | ||
| Soluble normal and mutated DNA sequences from single-copy genes in human blood | Q72268467 | ||
| Release of cell-free DNA into the bloodstream leads to high levels of non-tumor plasma DNA during tumor progression in rats | Q81792220 | ||
| SnapShot: non-small cell lung cancer | Q83727026 | ||
| Total 18F-FDG PET/CT Metabolic Tumor Volume Is Associated With Postoperative Biochemical Response in Patients With Metastatic Pheochromocytomas and Paragangliomas | Q86011781 | ||
| IS MEASUREMENT OF CIRCULATING TUMOR DNA OF DIAGNOSTIC USE IN PATIENTS WITH THYROID NODULES? | Q87938024 | ||
| Liquid Biopsy Technique May Allow Early Screening | Q88976539 | ||
| Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases | Q89107786 | ||
| Circulating Tumor DNA Assays in Clinical Cancer Research | Q89183577 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antineoplastic resistance | Q13416904 |
| metastasis | Q181876 | ||
| chromatin organization | Q15322272 | ||
| cell-free tumour DNA | Q19596321 | ||
| P304 | page(s) | 36 | |
| P577 | publication date | 2019-03-09 | |
| P1433 | published in | Molecular Cancer | Q15724585 |
| P1476 | title | The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis | |
| P478 | volume | 18 |
| Q92590013 | Cell-free DNA donor fraction analysis in pediatric and adult heart transplant patients by multiplexed allele-specific quantitative PCR: Validation of a rapid and highly sensitive clinical test for stratification of rejection probability |
| Q93078977 | Opportunities, Challenges, and Prospects in Electrochemical Biosensing of Circulating Tumor DNA and its Specific Features |
| Q89980656 | Role of non-coding RNAs and RNA modifiers in cancer therapy resistance |
| Q92349505 | Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy |
| Q89746470 | The paradox of cancer genes in non-malignant conditions: implications for precision medicine |
| Q90724935 | Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements |
Search more.